Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2
Journal of Experimental Medicine · 05.06.2023 · 220 (6)
DOI: 10.1084/jem.20221020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 21.03.2023. Verfasst von Tina Nguyen und 28 weiteren Autor:innen. Beteiligte Einrichtung: Garvan Institute of Medical Research , Darlinghurst, Australia. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Immunologic Deficiency Syndromes. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: National Health and Medical Research Council, American Association of Immunologists, Australian Research Council.
Abstract (Originalsprache)
Heterozygous loss-of-function (LOF) mutations in PIK3R1 (encoding phosphatidylinositol 3-kinase [PI3K] regulatory subunits) cause activated PI3Kδ syndrome 2 (APDS2), which has a similar clinical profile to APDS1, caused by heterozygous gain-of-function (GOF) mutations in PIK3CD (encoding the PI3K p110δ catalytic subunit). While several studies have established how PIK3CD GOF leads to immune dysregulation, less is known about how PIK3R1 LOF mutations alter cellular function. By studying a novel CRISPR/Cas9 mouse model and patients’ immune cells, we determined how PIK3R1 LOF alters cellular function. We observed some overlap in cellular defects in APDS1 and APDS2, including decreased intrinsic B cell class switching and defective Tfh cell function. However, we also identified unique APDS2 phenotypes including defective expansion and affinity maturation of Pik3r1 LOF B cells following immunization, and decreased survival of Pik3r1 LOF pups. Further, we observed clear differences in the way Pik3r1 LOF and Pik3cd GOF altered signaling. Together these results demonstrate crucial differences between these two genetic etiologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Garvan Institute of Medical Research , Darlinghurst, Australia.
- School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales Sydney , Kensington, Australia.
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney , Sydney, Australia.
- Department of Clinical Immunology, Royal Brisbane and Women's Hospital , Brisbane, Australia.
- Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University , Hiroshima, Japan.
- Department of Biosciences and Nutrition, Division of Clinical Immunology, Karolinska University Hospital Huddinge, Karolinska Institutet , Stockholm, Sweden.
ORCID-Profile: Tina Nguyen, Anthony Lau, Julia Bier, Kristen C Cooke, Helen Lenthall, Stephanie Ruiz-Diaz, Danielle T Avery, Henry Brigden, David Zahra, William A Sewell, Luke Droney, Satoshi Okada, Takaki Asano, Hassan Abolhassani, Zahra Chavoshzadeh, Roshini S Abraham, Nipunie Rajapakse, Eric W Klee, Andrew Williams, Melanie Wong, Christoph Burkhart, Gulbu Uzel, David R Croucher, David E James, Cindy S Ma, Robert Brink, Stuart G Tangye, Elissa K Deenick
Förderung
- National Health and Medical Research Council
- American Association of Immunologists
- Australian Research Council
- Jeffrey Modell Foundation
- Sydney Partnership for Health, Education, Research and Enterprise
- University of New South Wales
- John Brown Cook Foundation
Zitieren
APA
Nguyen, T., Lau, A., Bier, J., Cooke, K. C., Lenthall, H., Ruiz-Diaz, S., Avery, D. T., Brigden, H., Zahra, D., Sewell, W. A., Droney, L., Okada, S., Asano, T., Abolhassani, H., Chavoshzadeh, Z., Abraham, R. S., Rajapakse, N., Klee, E. W., Church, J. A., …, & Deenick, E. K. (2023). Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2. Journal of Experimental Medicine, 220(6). https://doi.org/10.1084/jem.20221020
Vancouver
Nguyen T, Lau A, Bier J, Cooke KC, Lenthall H, Ruiz-Diaz S, et al. Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2. Journal of Experimental Medicine. 2023;220(6). doi:10.1084/jem.20221020
BibTeX
@article{Nguyen2023,
author = {Nguyen, Tina and Lau, Anthony and Bier, Julia and Cooke, Kristen C and Lenthall, Helen and Ruiz-Diaz, Stephanie and Avery, Danielle T and Brigden, Henry and Zahra, David and Sewell, William A and Droney, Luke and Okada, Satoshi and Asano, Takaki and Abolhassani, Hassan and Chavoshzadeh, Zahra and Abraham, Roshini S and Rajapakse, Nipunie and Klee, Eric W and Church, Joseph A and Williams, Andrew and Wong, Melanie and Burkhart, Christoph and Uzel, Gulbu and Croucher, David R and James, David E and Ma, Cindy S and Brink, Robert and Tangye, Stuart G and Deenick, Elissa K},
title = {Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2},
journal = {Journal of Experimental Medicine},
year = {2023},
volume = {220},
number = {6},
doi = {10.1084/jem.20221020}
}
EUVIMED